Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Rigel Pharmaceuticals, Inc. (RIGL) -- Ignore unavailable to you. Want to Upgrade?

To: mopgcw who wrote (157)	11/17/2003 5:01:04 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 566

>> We believe that its hepatitis C small molecule program alone is worth more than $14 per share << That places, in their opinion, a value of better than $160M (giving the entire shareholders equity to this program) on a program where the first candidate just entered clinical testing. Price:book is about 4.5? I like the HCV program. I think it's great. An analyst who I respect (and who, to my knowledge, doesn't cover the stock) loves the program. But what is this weird "outperform" upgrade at a time where there is significant research premium and near-term risk of molecules going belly up in the clinic? Some sort of MPM effect? CSFB cut MYGN to underperform ("sell") this morning, from neutral. I find these observations to be strange.

To: mopgcw who wrote (157)	3/20/2008 11:13:11 AM
From: scaram(o)uche	Respond to of 566

Yup, same molecule! Thanks, George. I remembered the old HCV program, but didn't believe that six years could pass before such a vague (molecular target unknown) description would surface. >> Rigel discovered and retains all rights to R803, a small molecule candidate for hepatitis C that could enter the clinic by year-end 2003 << This molecule was the only reason that I was interested in Rigel, "back when". So....... Gilda Radnering...... never mind.